ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BEAT / dividends
DRIO (33) NEPH (59) TELA (35) PLRZ (34) ⌘ Pro Terminal →

Heartbeam Inc. (BEAT) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.41 -25.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.39

Heartbeam Inc. (BEAT) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $31.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BEAT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Heartbeam Inc. (NASDAQ: BEAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.41 (-25.64% 1D, market cap $31.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BEAT ranks #429 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BEAT compare to DRIO and NEPH in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BEAT?
▼

Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $59.2M in revenue (+6.3% YoY), -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.39 (-4.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (11)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.3% Base Target
$4 Bull$0 Base$0 Bear
📬 FREE BEAT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BEAT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY BEAT SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$0.40+2.5% Next Q
Q2 (-2Q)
37
Grade E$0.41-2.4% Next Q
Q3 (-1Q)
39
Grade E$0.40+2.5% Next Q
Current
42
Grade D-$0.41-7% Hist 90D α
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BEAT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BEAT currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.43) forces dealer call-delta covering toward $4.20.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BEAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BEAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BEAT)

  • ✓Walkthrough of BEAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BEAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.19%📐 HORIZONTAL RANGE
2026-11-03O $0.54H $0.55L $0.41C $0.41VOL 1.70M
RES: $0.95SUP: $0.27SMA50: $0.45SMA200: $0.85
$1.57$1.24$0.91$0.58$0.25RES $0.95SUP $0.27$0.412026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BEAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BEAT Butterfly Map → + Track BEAT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BEAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BEAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BEAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BEAT)

Health Care Rank #429 of 1015 ⚔️ DRIO vs BEAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BEAT vs. DRIO, NEPH, TELA, PLRZ)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Heartbeam Inc. (BEAT) ranks #429 by composite RQD confidence (42/100, grade D-) and #792 by equity capitalization ($31.0M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BEAT at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BEAT ACTIVE
Heartbeam Inc.
D- 42/100 — — -35.0% -25.64% $31.0M Benchmark Subject
DRIO
DarioHealth Corp.
E 33/100 — 56.6% -35.0% +1.00% $29.4M /drio-vs-beat →
NEPH
Nephros Inc.
C- 59/100 29.8x 61.9% 18.9% +2.21% $34.5M /neph-vs-beat →
TELA
TELA Bio Inc.
D- 35/100 — 67.7% -35.0% -1.33% $36.6M /tela-vs-beat →
PLRZ
Polyrizon Ltd.
E 34/100 — — -25.1% +4.74% $26.1M /plrz-vs-beat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779372 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heartbeam Inc. (BEAT) reported GAAP revenue of $59.2M (+6.3% vs. FY2024 revenue of $55.7M , and +38.0% cumulative change since FY2023) , GAAP net income of -$21.0M, operating cash flow of -$14.0M, and free cash flow of -$14.6M (+0.6% YoY). On the balance sheet, BEAT closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $59.2M -$21.0M -$14.0M -$14.6M $5.8M —
FY2024 (FY) 2024-12-31 $55.7M -$19.4M -$14.5M -$14.7M $3.3M —
FY2023 (FY) 2023-12-31 $42.9M -$14.6M -$12.1M -$12.1M — —

3. BEAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Heartbeam Inc. (NASDAQ: BEAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.41 (-25.64% 1D, market cap $31.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BEAT ranks #429 in composite RQD confidence.

How does BEAT compare to DRIO and NEPH in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $29.4M) and NEPH (Nephros Inc.) posts a C- grade (59/100 RQD, P/E 29.8x, ROIC 18.9%, cap $34.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BEAT?

Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $59.2M in revenue (+6.3% YoY), -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BEAT trading relative to its 50-day, 200-day, and 52-week technical levels?

BEAT last traded at $0.41 (-25.64% on volume of 4,134,889 shares), positioning the stock -8.89% below its 50-day simple moving average ($0.45) and -51.76% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.35 to $4.00, BEAT sits at the 1.6% percentile with a 14-day RSI of 62.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.00 to $0.46).

Direct Sub-Reports: BEAT RQD Cockpit BEAT 12M Forecast BEAT Earnings & Move BEAT Dividends & DRIP BEAT Insiders & 13F BEAT Whale Options BEAT Profit Sankey BEAT News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BEAT — Heartbeam Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Heartbeam Inc. (BEAT) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.41 (-25.64% 1D, market capitalization $31.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Heartbeam Inc. (BEAT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry..0B in that section, while the market data section reports $30.4M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Heartbeam Inc. (BEAT) reported $59.2M in annual revenue (up from $55.7M in FY2024, +6.3% YoY) and -$21.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.9M revenue, -$14.6M net income) through FY2025, BEAT scaled operating cash flow to -$14.0M and free cash flow to -$14.6M, backed by $5.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.35 – $4.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), BEAT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BEAT sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $59.2M and free cash flow of -$14.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BEAT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BEAT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Heartbeam Inc. (BEAT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BEAT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BEAT Bull vs. Bear Conversation Board — What's Your Call at $0.41?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BEAT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BEAT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $0.64 (+16.4%)
📌 Pinned Debate

BEAT (D- • RQD 42/100) operating leverage in Medical/Dental Instruments is mispriced at $0.55

Picked up a starter position in BEAT in my $100K Virtual Cash book at $0.55. BEAT (D- • RQD 42/100) operating leverage in Medical/Dental Instruments is mispriced at $0.55. Trading inside a $0.35–$4.00 52-week range with 0.0% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.47 (-14.5%)
Spot @ $0.55

Negative ROIC of -35%, zero FCF yield, and an FY 2025 FCF of -$14.6M against $4.4M cash point to a balance sheet with limited cushion.

Careful chasing BEAT at $0.55. Negative ROIC of -35%, zero FCF yield, and an FY 2025 FCF of -$14.6M against $4.4M cash point to a balance sheet with limited cushion.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.47 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%